GSK3993129 / GSK - LARVOL DELTA

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults (clinicaltrials.gov) - P1 | N=339 | Completed | Sponsor: GlaxoSmithKline | Phase classification: P1/2 ➔ P1 | Active, not recruiting ➔ Completed

Phase classification • Trial completion • Cytomegalovirus Infection • Infectious Disease

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults (clinicaltrials.gov) - P1/2 | N=333 | Active, not recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Jun 2029 ➔ Jun 2025 | Trial primary completion date: Jun 2029 ➔ Jun 2025

Trial completion date • Trial primary completion date • Cytomegalovirus Infection • Infectious Disease

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults (clinicaltrials.gov) - P1/2 | N=329 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting

Enrollment closed • Cytomegalovirus Infection • Infectious Disease • CD4

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults (clinicaltrials.gov) - P1/2 | N=329 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Mar 2029 ➔ Jun 2029 | Trial primary completion date: Feb 2024 ➔ Jun 2029

Trial completion date • Trial primary completion date • Cytomegalovirus Infection • Infectious Disease • CD4

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults (clinicaltrials.gov) - P1/2 | N=320 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Nov 2024 ➔ Mar 2029 | Trial primary completion date: Aug 2023 ➔ Feb 2024

Trial completion date • Trial primary completion date • Cytomegalovirus Infection • Infectious Disease • CD4

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults (clinicaltrials.gov) - P1/2 | N=320 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Mar 2024 ➔ Nov 2024 | Trial primary completion date: Mar 2024 ➔ Aug 2023

Trial completion date • Trial primary completion date • Cytomegalovirus Infection • Infectious Disease • CD4

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults (clinicaltrials.gov) - P1/2 | N=320 | Recruiting | Sponsor: GlaxoSmithKline | Trial primary completion date: Sep 2022 ➔ Mar 2024

Trial primary completion date • Cytomegalovirus Infection • Infectious Disease • CD4